

Press Release

Lonza to Exhibit Innovative Research Solutions for Transfection, Endotoxin Detection and ADME-Tox Testing at SLAS2017

Cologne, Germany / Basel, Switzerland, 01 December 2016 – On 4-8 February 2017, Lonza will be exhibiting at SLAS2017, hosted by the Society for Laboratory Automation and Screening in Washington, DC (USA). In addition to presenting a poster explaining the efficiency and accuracy of automated endotoxin testing, the Lonza team (located in Booth 547) will showcase how its latest equipment, reagents and software can be utilized to create innovative research solutions for transfection, endotoxin detection and ADME-Tox testing, thereby increasing efficiency and throughput in the laboratory.

Poster Presentation: Automation of Endotoxin Testing

Greg Alberts, Global Subject Matter Expert at Lonza, will present a poster titled "Streamlining Your QC Testing: The Efficiency and Accuracy of Automated Endotoxin Testing and Process Optimization." Data in the poster will show the ability of robotic systems to reproducibly and reliably perform the preparation of standards, complex routines and dilution schemes necessary to endotoxin testing, and demonstrate the efficiency, accuracy and effectiveness of an automated solution when implemented in a large-scale fashion.

Improving the Scalability of Transfection

At Booth 547 Lonza will showcase the 4D-Nucleofector™ LV Unit and the HT Nucleofector™ Device, both of which use Nucleofector™ Technology to enable efficient transfection of cells. This method of electroporation allows scientists to use minimal amounts of substrate to transfect a multitude of different cell types, including stem cells, primary cells, and cell lines that have previously proven challenging to transfect. Combining this technology with the 4D-Nucleofector™ LV Unit provides a closed system for sterile transfection of up to 1×10^9 cells, and enables scaling-up of transfections carried out using Lonza's 4D-Nucleofector™ X Unit, without the need for re-optimization.

<http://www.lonza.com/lv-unit>

<http://www.lonza.com/products-services/bio-research/transfection/nucleofector-devices/384-well-nucleofector-system.aspx>

Press Release

Automating QC Testing for the Pharmaceutical Industry

At SLAS2017, Lonza's experts will demonstrate how the WinKQCL™ Endotoxin Detection and Analysis Software can be integrated into robotic platforms. These automated workflow solutions allow scientists to simply set up an assay and "walk away," reducing ergonomic stress caused by manual pipetting and mitigating human errors.

<http://www.lonza.com/products-services/pharma-biotech/informatics/winkqcl-endotoxin-detection-analysis-software.aspx>

Providing Resources for ADME-Tox Testing

Lonza's acquisition of Triangle Research Laboratories (TRL) in June 2016 has enabled Lonza to expand its portfolio of products and services to now include a diverse range of high-quality fresh and cryopreserved human and animal hepatocytes, as well as supporting media and cell culture products. These cells and supporting materials are invaluable *in vitro* drug screening tools, enabling drug candidates to be assessed for a range of characteristics, including drug-drug interactions, drug transporter activity, metabolism and toxicity.

<http://www.lonza.com/products-services/bio-research/adme-tox.aspx>

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
www.lonza.com

Press Release

Lonza Contact Information

Lonza Cologne GmbH	Lonza Group Ltd
Manager Marketing	Head Corporate
Communications	Communications
Petra Haberkamm	Dominik Werner
Tel +49 221 991990	Tel +41 61 316 8798
Fax +49 221 99199498	Fax +41 61 316 9540
marcom.lbs@lonza.com	dominik.werner@lonza.com

Lonza Group Ltd
Head External
Communications
Constance Ward
Tel +41 61 316 8840
Fax +41 61 316 9840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.